Peluntamig targets DLL3 and CD47, potentially enhancing immune recognition and attack on cancer cells. The SKYBRIDGE study is a phase 1/2 trial assessing peluntamig's safety and efficacy in ...

Yale researchers recently discovered new genes that could be used to test potential treatment options for a rare form of aggressive lung cancer. Each year, about 6,000 Americans — roughly 3 percent of ...

A meta-analysis of safety and efficacy of datopotamab deruxtecan and sacituzumab govitecan for second line treatment of metastatic non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract ...

Experts discuss the integration of GLP-1 receptor agonists in treating neuroendocrine tumors, highlighting safety concerns ...

A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated ...

A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors, according to new clinical trial ...

Effective coordination among multidisciplinary team and individualized management strategies has emerged as a cornerstone of optimal NET care.

The Journal of Clinical Oncology podcast, hosted by Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of Clinical Oncology.

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited ...